The U.S. health regulator has approved expanding the use of Revance Therapeutics' Daxxify to treat a painful neck muscle condition, intensifying the anti-wrinkle injection's rivalry with AbbVie's ...
After debuting in the aesthetics market with Daxxify last year, Revance has made its way to the potentially lucrative therapeutic space. With a Monday FDA nod to treat cervical dystonia in adults, ...
The US Food and Drug Administration (FDA) has expanded the indiction for daxibotulinumtoxinA-lanm injection (Daxxify, Revance Therapeutics) for the treatment of cervical dystonia in adults, the ...
Credit: Revance Therapeutics. Daxxify is supplied as a lyophilized powder for reconstitution in single-dose 50 Unit and 100 Unit vials. The Food and Drug Administration (FDA) has approved Daxxify ® ...
Revance Therapeutics' share price has been characterised by volatility ever since its IPO - but today shares trade close to an all-time low. The company's focus is on maximising the potential of ...
Aug 14 (Reuters) - The U.S. health regulator has approved expanding the use of Revance Therapeutics' Daxxify (RVNC.O), opens new tab to treat a painful neck muscle condition, intensifying the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback